Nuvalent Inc
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsNuvalent is a clinical-stage biopharmaceutical company developing targeted kinase inhibitors for ROS1- and ALK-positive non-small cell lung cancer.
What they do
Nuvalent designs small-molecule kinase inhibitors aimed at overcoming resistance, selectivity issues, and brain metastases seen with existing therapies. Its lead candidates are zidesamtinib (ROS1-selective) and neladalkib (ALK-selective), both in clinical development for NSCLC. The company has no approved products and no revenue.
Revenue drivers
- Zidesamtinib (NVL-520) — Investigational ROS1-selective inhibitor for ROS1-positive NSCLC; NDA under FDA review with a PDUFA date of September 18, 2026; potential launch in 2026.
- Neladalkib — Investigational ALK-selective inhibitor for ALK-positive NSCLC; NDA submitted to FDA in May 2026 for TKI pre-treated patients.
- No current revenue — Pre-commercial; all financials are R&D and operating expenses funded by equity.
Recent performance
Net loss for 2025 was $-425.4 million, up from $-260.8 million in 2024, with diluted EPS of $-5.85. Operating cash flow was $-275.2 million in 2025. At March 31, 2026, cash and equivalents were $159.7 million, total assets $1.33 billion, and shareholder equity $1.17 billion.
Strategy
The company is advancing zidesamtinib and neladalkib toward U.S. regulatory approval and building commercial infrastructure. It plans to submit zidesamtinib data from the TKI-naïve cohort in second half 2026 to support label expansion. It continues to explore earlier treatment paradigms and broader solid tumor indications, and is investing in pipeline expansion beyond the lead programs.
Risks
- Regulatory approval risk — Zidesamtinib and neladalkib are investigational; FDA approval is not assured and could be delayed or denied.
- Clinical trial risk — Phase 2/3 trials may fail to confirm efficacy or safety, jeopardizing registrational plans.
- Cash burn and dilution risk — With $159.7 million cash and $275 million annual operating cash burn, additional funding will likely be needed, potentially diluting shareholders.
- Competition risk — Existing ROS1/ALK inhibitors and emerging therapies may limit commercial uptake even if approved.
Outlook
Management expects an FDA decision on zidesamtinib by September 18, 2026 and a potential U.S. launch in 2026, pending approval. It plans to submit zidesamtinib TKI-naïve data in second half 2026 and continue advancing neladalkib's regulatory pathway. The company reiterated key milestones for 2026, including label expansion and earlier-stage pipeline progress.